Loading...

AUTL AUTOLUS THERAPEUTICS PLC Company Mergers 8-K Filing

TLS

TL

AUTOLUS THERAPEUTICS PLC

(AUTL)

2026 8-K

Financial Results Update

New Agreement Signed

Financial Update

Director Appointment

Financial Update

Annual Report and AGM Notice

Financial Statements

Investor Update

Management Changes

Financial Results

Corporate Update

Financial Results

Corporate Update

Management Change

Lease Amendment

Financial Results and Corpo...

Financial Statements and Ex...

Clinical Study Data Announc...

Financial Results and Corpo...

Rescheduled Conference Call...

Management Changes

Accounting Error

Conference Call Transcript

Financial Results and Manag...

Corporate Presentation

Underwriting Agreement

License and Option Agreemen...

FDA Accepts BLA for obecabt...

Appointment of New Director

Management Changes

ASH Annual Meeting Presenta...

Regulation FD Disclosure

External Links:

On January 21, 2026, Autolus Therapeutics plc's subsidiary signed a 10-year Master Service Agreement with AGC Biologics for the manufacture of lentiviral vector, committing to purchase at least 14 batches and €25 million worth of products in the first 7 years.

AI Assistant

AUTOLUS THERAPEUTICS PLC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.